exemestane
information and resources from the National Cancer Institute
NCI Thesaurus | exemestane
A synthetic androgen analogue. Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. NCI Thesaurus | exemestane
A synthetic androgen analogue. Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens.
Aromasin
Treatment of advance breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Pharmacia & Upjohn Company Oct 21 1999
|
|
|
|
news articles
Exemestane May Help Downgrade Tumours Scheduled for Mastectomy to ... Mar 27, 2006
DG News NICE, FRANCE -- March 27, 2006 -- The aromatase inhibitor exemestane (Aromasin) could make breast-conserving surgery possible in breast cancer patients with ...
A 62-Year-Old Woman With a New Diagnosis of Breast Cancer Mar 21, 2006
Journal of American Medical Association (subscription), ...receptors. Adjuvant endocrine therapy was recommended. Exemestane was considered; however, it was not covered by her insurance. She ...
New findings in breast cancer therapy described Mar 30, 2006
Therapeutics Daily (subscription) (press release), The third-generation aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole offer new treatment options, although their efficacy has not been ...
Neoadjuvant Aromatase Inhibitors May Be as Effective as ... Mar 27, 2006
DG News ...were randomised to pre-operative treatment with either an aromatase inhibitor -- consisting of either anastrazole (Arimidex) or exemestane (Aromasin) -- or ...
Aromasin® Improves Breast Cancer Outcomes Without Compromising ... Feb 28, 2006
Cancer Consultants (press release), Breast cancer patients who switched to Aromasin® (exemestane) after 2-3 years of Nolvadex® (tamoxifen) reported a similar quality of life to patients who ...
Pay attention to your breasts Mar 11, 2006
Malaysia Star, ...cancer cells. There are three aromatase inhibitors available in the market now ie anatrazole, letrozole and exemestane . Recently ...
ExCel Breast Cancer Prevention Study Back On Track Mar 4, 2006
Medical News Today (press release), ...said, “ExCel is back on track with a redesigned protocol that will look at the effectiveness of one of the aromatase inhibitors, exemestane (AROMASIN®), as ...
New Drug Could Prevent Breast Cancer 21 Dec 2005
13WHAM-TV, The trial is comparing a placebo to a drug called Exemestane, which blocks an enzyme in a woman's body that helps convert stored hormones into estrogen. ...
Drugs work on estrogen to fight cancer 21 Dec 2005
News 8 Austin, ...estrogen. There are three AIs approved by the FDA including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara). ...
Fracture Rates Similar Between with Tamoxifen and Exemestane ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- Researchers said that fracture rates are similar after 2 years of treatment with tamoxifen or exemestane in the ...
Researchers seek volunteers for breast cancer study Dec 14, 2005
Newark Star Ledger, The ExCel Research Study, which will include 4,500 postmenopausal women, involves the drug exemestane, currently used to treat millions of women with breast ...
Five-Year Data from Austrian Trial Shows Significant Benefit in ... Dec 14, 2005
DG News ...trials have shown that efficacy is improved when a patient is switched from tamoxifen to an aromatase inhibitor such as letrozole, anastrozole or exemestane. ...
Breast Cancer Treatment Dec 16, 2005
Food Consumer, 137. Coombes RC, Hall E, Gibson LJ, et al.: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary ...
New breast cancer drug trial seeks volunteers Dec 5, 2005
Salem News, A new international trial is underway to find out if one particular aromatase inhibitor, called exemestane (marketed as Aromasin by Pfizer), would do just that ...
(PRN) US Oncology Research Network Presenting Numerous Studies at ... Dec 11, 2005
Houston Chronicle, Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal ...
ARIMIDEX (anastrozole) Featured in Studies Evaluating Impact of ... Dec 9, 2005
PharmaLive.com (press release), Also presented today (Poster # 2052) were initial findings from the Letrozole, Exemestane, and Anastrozole Pharmacodynamics (LEAP) trial, which provides direct ...
Femara gets approval for early adjuvant use in UK Dec 8, 2005
Pharma Times (subscription), ...should aid Femara as it competes with the other main aromatase inhibitors, AstraZeneca's Arimidex (anastrozole) and Pfizer's Aromasin (exemestane, and add to ...
US Oncology Research Network Presenting Numerous Studies at San ... Dec 11, 2005
PR Newswire (press release), These sessions included: * Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a ...
|
|
